Consistent with our data, previous studies showed that high expression of FPR1 corresponded with poor survival in neuroblastoma and gastric cancer patients21, 26, and targeting FPR1 with an antagonist attenuated astrocytoma cell motility and prolonged the survival of tumour-bearing mice16. The gene discussed is FPR1; the disease is astrocytoma (excluding glioblastoma).